

1 **Full Title (90 characters, max: 200):** The role of sub-genomic RNA in discordant results from
2 RT-PCR tests for COVID-19.

3
4 **Short Title (64 characters, max: 70):** Sub-genomic RNA may cause inconclusive RT-PCR
5 tests for COVID-19.

6
7 **Authors:** Noah B. Toppings¹, Lisa K. Oberding², Yi-Chan Lin³, David Evans³, Dylan R.
8 Pillai^{1,2,4,5}.

9
10 **Affiliations:** 1. Department of Microbiology, Immunology, and Infectious Diseases, University
11 of Calgary, Calgary, AB, Canada
12 2. Department Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
13 3. Department of Medical Microbiology & Immunology and Li Ka Shing Institute of Virology,
14 University of Alberta, Edmonton, Alberta, Canada
15 4. Clinical Section of Microbiology, Alberta Precision Laboratories, Calgary, AB, Canada
16 5. Clinical Section of Infectious Diseases, Department of Medicine, University of Calgary,
17 Calgary, AB, Canada
18

19 **Abstract (271 words, Max: 300):** Reverse transcription-PCR (RT-PCR) is the standard method
20 of diagnosing COVID-19. An inconclusive test result occurs when one RT-PCR target is positive
21 for SARS-CoV-2 and one RT-PCR target is negative within the same sample. An inconclusive
22 result generally requires retesting. One reason why a sample may yield an inconclusive result is
23 that one target is at a higher concentration than another target. It was hypothesized that
24 concentration differences across targets may be due to the transcription of sub-genomic RNA, as
25 this would result in an increase in the concentration of gene targets near the 3' end of the SARS-
26 CoV-2 genome. A panel of six digital droplet (dd)PCR assays was designed to quantitate the
27 ORF1, E-gene, and N-gene of SARS-CoV-2. This panel was used to quantify viral cultures of
28 SARS-CoV-2 that were harvested during the eclipse phase and at peak infectivity in such a way
29 as to maximize gene-to-gene copy ratios. Eleven clinical nasopharyngeal swabs were also tested
30 with this panel. In culture, infected cells showed higher N-gene/ORF1 copy ratios than culture
31 supernatants. Both the highest specific infectivity (copies/pfu) and the highest differences
32 between gene targets were observed at 6 hours post-infection (eclipse phase) in infected cells.
33 The same trends in the relative abundance of copies across different targets observed in infected
34 cells was observed in clinical samples, though trends were more pronounced in infected cells.
35 This study showed that a greater copy number of N-gene relative to E-gene and ORF1 transcripts
36 could potentially explain inconclusive results for some RT-PCR tests on low viral load samples.
37 The use of N-gene RT-PCR target(s) as opposed to ORF1 targets for routine testing is supported
38 by this data.
39

40

41

42 **Author Summary (167 words, required: 150-200 words):** This paper provides insight into a
43 drawback of the standard method of testing for COVID-19 (RT-PCR). The results presented here
44 propose an explanation for why inconclusive results sometimes occur with this method. These
45 results can aid microbiologists in the interpretation of inconclusive test results. These results can
46 also aid in decisions about which COVID-19 test a laboratory should use, as there are a plethora
47 of options available. This is important because this standard testing method will remain a critical
48 tool — globally — for managing the COVID-19 pandemic and any future viral pandemics and
49 epidemics. Thus, it is important to investigate every facet of the testing method. The findings
50 presented here are applicable to any virus which makes sub-genomic transcripts as part of its life
51 cycle. Trends observed in viral cultures are presented alongside the same trends observed in
52 clinical samples. Unlike similar papers in the field, this paper did not strive to develop a new
53 methodology or tool.

54

55

56

57

58

59

60

61

62

63

64

65 **Introduction:**

66 RT-PCR is the standard method of diagnosing COVID-19 in a laboratory (1–4). RT-PCR tests
67 for COVID-19 qualitatively detect SARS-CoV-2 RNA from patient samples (1–4). SARS-CoV-
68 2 is a +sense RNA virus of the *Coronaviridae* family with a genome approximately 29,903
69 nucleotides long (5,6). Diagnostic RT-PCR tests which detect SARS-CoV-2 RNA usually
70 identify two or three individual RT-PCR targets in order to increase one’s confidence in the
71 results, control for possible errors, and provide redundancy in the case of mutations which effect
72 primer binding (7–10). Thus, the qualitative result of the RT-PCR test is reached by interpreting
73 the results of all the individual RT-PCR targets. Table 1 is an example of an interpretation guide
74 for a typical RT-PCR test for COVID-19.

75 For each clinical sample, all the SARS-CoV-2 RT-PCR targets usually yield the same
76 qualitative result and yield similar Ct values. This is because viral replication produces full-
77 length SARS-CoV-2 genomes which contain all genes in equal proportions (Figure 1)(11,12).
78 However, sometimes only a single SARS-CoV-2 assay will yield a positive result, making the
79 test result inconclusive. Samples with low viral loads are more likely to yield an inconclusive
80 result in this way (10). The biological and clinical significance of low viral load (high Ct value)
81 samples is under investigation as some reports suggest these samples are rarely infectious
82 (13,14).

83 Some studies have reported the prevalence of inconclusive COVID-19 RT-PCR test
84 results. Vogels *et al.* observed that 7.9% of samples positive for at least one RT-PCR target were
85 inconclusive (not positive for both targets) (15). Out of 286 samples tested, Jawade *et al.*
86 observed 19 (6.64%) inconclusive samples and 126 (44.1%) positives (16). With the specific kit

87 Jawade *et al.* used, a sample was inconclusive only when the RdRP target was negative and the E
88 gene target was positive (16,17).

89 When a sample is deemed to be inconclusive, retesting of the sample is generally
90 recommended (2,17). Retesting consumes valuable time and reagents; decreasing testing
91 throughput. Thus, it is advantageous to understand the causes of inconclusive test results so they
92 can be minimized.

93 There are various reasons why an RT-PCR test might yield an inconclusive result.
94 Reasons include, differences in sensitivity between primer/probe sets, mistakes setting up the
95 reaction, primer-template mismatches caused by a mutation in the virus, differences in the
96 template concentrations of different targets, among other factors, and a combination of these
97 factors.

98 As an example, Vogels *et al.* determined that the US CDC N1 primer/probe set was more
99 sensitive than the US CDC N2 primer/probe set (15). Using a Ct value positivity cutoff of 38,
100 Vogels *et al.* tested 172 clinical samples with the US CDC N1 and N2 primer/probe sets (15).
101 From this set, 58/172 (33.7%) were positive while 5/172 (2.9%) were inconclusive, representing
102 7.9% of samples positive for at least one target (15). All 5 inconclusive samples were positive for
103 the more sensitive N1 target and negative for the N2 target (15).

104 Documented examples of specific SARS-CoV-2 mutations causing inconclusive RT-PCR
105 test results include the C26340U transition (8) and the Δ 69-70 deletion in the spike protein of the
106 B.1.1.7 lineage (18). These mutations caused failure of the E gene target with the Roche cobas
107 test (8), and the spike gene target using the ThermoFisher TaqPath probe (18), respectively. This
108 study focuses solely on inconclusive results caused by differences in the template concentrations
109 of different targets.

110 We hypothesized that discrepancies in the qualitative result of different RT-PCR assays
111 on SARS-CoV-2-suspected clinical samples can largely be explained by a greater abundance of
112 gene copies near the 3' end of the genome due to the transcription of sub-genomic RNA. To test
113 this hypothesis, a panel of six ddPCR assays was designed to quantify the abundance of different
114 SARS-CoV-2 RT-PCR targets. Next, SARS-CoV-2 was cultured *in vitro* to observe the relative
115 abundance of different targets under ideal conditions. Finally, a set of clinical samples was tested
116 to observe trends in the relative abundance of different targets. This study showed that greater
117 copies of the N-gene relative to the E gene and ORF1 could potentially explain inconclusive
118 results of some RT-PCR assays on low viral load samples.

119
120 **Results:**

121 **Droplet Digital PCR Methodology Validation:** To quantify different regions of the SARS-
122 CoV-2 genome, six pre-existing RT-PCR assays intended for routine COVID-19 diagnostic
123 testing were adapted to ddPCR. In the case of the US CDC N1 and N2 targets, these had already
124 been adapted by Bio-Rad (19). As the objective of this study was to better understand routine
125 diagnostic RT-PCR testing, no primer sets for research purposes were used or designed.

126 Differences in the sensitivity of various primer/probe sets could give the false appearance
127 of a difference in target gene abundance. However, this was ruled out by using the Exact
128 Diagnostics SARS-CoV-2 (quantitative) Standard. The counts using this standard for each target
129 are shown in Figure S2. Assays that did not quantitate the standard accurately were considered
130 non-quantitative and were excluded from this study. This experiment used two ddPCR assays
131 targeting each of the following open-reading frames: nucleocapsid (N), envelope (E), and
132 ORF1ab. Differences in the relative abundance of different SARS-CoV-2 targets (as determined

133 by ddPCR counts) could be the result of unequal transcription of targets (sub-genomic RNA), or
134 the unequal degradation of RNA targets.

135 As this study used ddPCR to investigate the performance of RT-PCR, it was important to
136 evaluate the performance of ddPCR relative to RT-PCR. To this end, RT-PCR and ddPCR was
137 performed on three replicate serial 10-fold dilutions of a clinical sample (Figure 2). Six standard
138 curves were prepared from this data (Figure 3). These curves all showed highly linear
139 relationships between RT-PCR Ct values and $\log_{10}(\text{copies}/\mu\text{L})$ from ddPCR across the dilution
140 series with only one adjusted R^2 value being below 0.97 (Figure 3). The exception being the IP2
141 ORF1 target due to high variance from the RT-PCR (Figures 2 and 3). The IP2 ORF1 RT-PCR
142 coefficients of variation were on average 6.84-fold higher than for the other five RT-PCR targets.
143 However, all six linear regressions had overlapping 95% CI's for both the coefficient and the
144 constant (Figure 3). This suggests that these two techniques yield highly concordant results and
145 supports applying conclusions from ddPCR to RT-PCR.

146 The RNase P gene of Vero CCL81 cells differs from that of human RNase P such that
147 there are four primer-template mismatches; two in each primer (20–24). This was predicted to
148 greatly decrease the sensitivity of this primer/probe set (25). Thus, RNase P ddPCR counts from
149 Vero CCL81 cells were not used for quantitative comparisons.

150 **SARS-CoV-2 *in vitro* Cultures:** Vero CCL81 cells were infected with SARS-CoV-2 at a
151 multiplicity of infection of 0.01 and grown for 48 hours. A sample of the culture supernatant and
152 the adherent cells was taken at 6 and 48 hours post-infection (HPI). The 6 HPI time point occurs
153 just after the eclipse phase of the virus (26) while the 48 HPI time point occurs at peak infectivity
154 (our unpublished data). The cell lysate was expected to be the exclusive site of viral replication
155 while the culture supernatant was expected to contain released virions and minimal cell contents

156 (27). Figure 4A shows the infectivity of viral cultures over time, with overlapping infectivity
157 between supernatants and cell lysates at 6 HPI and around a $4\log_{10}$ increase in infectivity by 48
158 HPI with cell lysates more infectious than the supernatants at 48 HPI. Specific infectivity
159 (copies/pfu) was highest in cell lysates and at 6 HPI opposed to 48 HPI (Figure 4B).

160 Similar trends observed for specific infectivity were also observed in the relative
161 abundance of different gene targets (Figure 5). The greatest differences in copies between targets
162 was observed in cell lysates, opposed to supernatants (Figure 5). Between the two supernatants,
163 the greatest differences between targets were observed at 6 HPI while for cell lysates, however,
164 the greatest differences were observed at 48 HPI (Figure 5). Within a single target, higher
165 variances between replicates was observed at 6 HPI rather than at 48 HPI (Figure S3).

166 In both the supernatant and cell lysate at 6 HPI, the highest counts were from the N gene
167 targets with relatively similar counts from the E gene and ORF1 targets (Figure 5). In the
168 supernatant at 48 HPI, the APL E gene target yielded the highest counts with relatively similar
169 counts between the remaining 5 targets. In the cell lysate at 48 HPI, the highest and lowest
170 counts were from the N-gene and ORF1 targets, respectively, with the two E-gene targets
171 yielding intermediate counts (Figure 5). In summary, this viral culture experiment shows that
172 under various conditions (especially in infected cells or during the eclipse phase) different
173 SARS-CoV-2 gene targets are present at different concentrations in a manner consistent with the
174 transcription of sub-genomic RNA. The question then became whether or not these same trends
175 observed *in vitro* could be observed *in vivo* in clinical samples from people infected with SARS-
176 CoV-2.

177 **Analysis of Clinical Nasopharyngeal Swabs:** To assess whether the trends observed *in vitro* could
178 also be observed *in vivo*, eleven nasopharyngeal swabs from people confirmed to have COVID-19
179 were tested with the panel of six ddPCR targets. The range of RT-PCR Ct values of the eleven clinical
180 nasopharyngeal swabs was 19.04 to 31.95 (US CDC N2 target) (Table S1). The absolute abundance,
181 and relative abundance, of each ddPCR target for the eleven clinical samples tested is shown in
182 Figures 6 and 7, respectively. Clinical samples yielded the highest counts with the N-gene targets
183 (Figure 7). The E-gene targets and IP2 ORF1 yielded similar counts while the China CDC ORF1 count
184 was the lowest across the samples (Figure 7). Thus, the same trends in the relative abundance of
185 different ddPCR targets observed in viral cultures was also observed in clinical samples.

186 For a detailed comparison of the relative abundance of ddPCR targets in clinical samples to
187 that of cultures, the mean copy ratios from the cultured samples were subtracted from the mean copy
188 ratios from the clinical sample set (Figure 8). The more similar the copy ratios were, the paler the
189 matrix (Figure 8). The N-gene/ORF1 ratios were higher in the cell lysates than in clinical samples
190 (Figure 8). The same held true for the E-gene/ORF1 ratios (Figure 8). Visually, and numerically, the
191 clinical samples were most similar to the culture supernatants at 6 HPI (eclipse phase) (Figure 8). The
192 N-gene/ORF1 ratios in the culture supernatants at 48 HPI were less than the ratios in clinical samples
193 (Figure 8). In summary, clinical samples had differences between target copies intermediate that of cell
194 lysates and culture supernatants (Figure 8).

195 196 **Discussion:**

197 The results presented here propose an explanation for some inconclusive COVID-19 RT-PCR test
198 results. Specifically, when inconclusive RT-PCR results occur due to an ORF1 target being negative
199 and an N gene target being positive. In such cases, this may be due to fewer ORF1 copies in the
200 sample.

201 Data support the use of diagnostic RT-PCR assays targeting the N-gene exclusively, as opposed to
202 targeting the E-gene or ORF1, for optimal sensitivity. This is because, on average, more N-gene copies
203 were detected in clinical samples than ORF1 copies. However, the concentration of ORF1 copies in
204 clinical and viral culture samples in this study was always above the limit of detection of ddPCR.

205 The reason why clinical samples may have more N-gene copies than ORF1 copies could be
206 because clinical samples do not merely contain virions but contain infected cells which contain sub-
207 genomic RNA encoding the N-gene. However, this study never specifically identified sub-genomic
208 RNA because the diagnostic tests in question do not specifically identify sub-genomic RNA. Thus, it
209 cannot be ruled out that unequal degradation of genomic RNA could explain the trends observed. All
210 assays amplified their specific target regardless of whether it was in genomic, sub-genomic, sense, or
211 antisense transcripts.

212 Similar studies have been published describing panels of optimized ddPCR assays for SARS-
213 CoV-2 (28,29). However, the goal of this study was to understand a deficiency in RT-PCR tests, not to
214 develop a tool for understanding SARS-CoV-2 biology nor was the goal to develop a diagnostic test
215 for clinical use. Nonetheless, the trends of E-gene and N-gene copies identified here are congruent
216 with the findings of Telwatte *et al.* (both papers) in that genes nearest the 3' end of the genome have
217 greater copy numbers than those in ORF1 (28,29). Consistent with the results presented here,
218 Dimcheff *et al.* found – using RT-qPCR – that N-gene sub-genomic RNA was more detectable than E
219 gene sub-genomic RNA after testing 185 clinical nasopharyngeal swabs (30). However, Dimcheff *et*
220 *al.* reported a minimal difference between the mean Ct values of the US CDC N1 and Corman E RT-
221 qPCR assays across all 185 samples (mean Ct of 25.6 S.D. 5.6 versus 25.76 S.D. 5.69, respectfully)
222 (30). It is not clear if a sample-wise comparison of US CDC N1 and Corman E Ct values would show
223 significantly lower Ct values for US CDC N1. Likewise, the mean copies/mL for US CDC N1 and

224 Corman E across all clinical samples in this study were not close to significantly different ($p = 0.84$
225 with Mann-Whitney U test and $p = 0.51$ with two-sample t-test). Nonetheless, this study reported that
226 US CDC N1 copies were significantly higher than Corman E copies on a sample-wise basis (Corman
227 E/US CDC N1 = 0.65 95% C.I. 0.60-0.71) (Figure 7). Furthermore, both E-gene ddPCR targets had
228 significantly lower counts than either N gene ddPCR target, with the E-gene/N-gene ratios ranging
229 from 0.64 to 0.66 (Figure 7). This apparent disagreement could be partially resolved with a sample-
230 wise analysis of Ct values or else it could be explained by the smaller sample size of this study or
231 differences in the quantitative accuracy of ddPCR versus RT-PCR.

232 Marchio *et al.* performed a ddPCR study reminiscent of this study and obtained congruent
233 results from clinical samples and cultured virus (31). In viral cultures at 24 HPI, the highest copy
234 target was the N-gene followed by the E-gene and finally the IP2 ORF1 and IP4 ORF1 targets (31).
235 Importantly, these results were observed across three different mammalian cell lines, none of which
236 were used in this study (31). Thus, the results from viral culture presented here are clearly not
237 restricted to a single cell line, increasing their relevance to understanding clinical samples (31). More
238 N-gene positive droplets than ORF1 positive droplets in 9/16 clinical samples were observed, whereas
239 this study observed higher N-gene counts compared to ORF1 counts in 11/11 clinical samples (Figure
240 6) (31). However, further analysis of this was not provided, preventing more comparisons between
241 these two studies (31). Interestingly, ddPCR single-target positivity in five samples which were
242 negative by RT-PCR was noted. Of these five, four were positive for only the N-gene target while one
243 was only positive for the IP4 ORF1 target. Furthermore, the results of this study and Marchio *et al.*
244 support the use of RT-PCR assays targeting the N-gene, opposed to targeting the E-gene or ORF1 (31).
245 Hu *et al.* is the only study besides this study we have found to date which uses ddPCR to investigate

246 inconclusive RT-PCR results (10). However, only two ddPCR targets were used in Hu *et al.* (10).
247 These authors also conclude that N gene confers an advantage in terms of analytical sensitivity.

248 Alexandersen *et al.* used next-generation sequencing in combination with RT-PCR to
249 understand the relative abundance of different SARS-CoV-2 sequences in clinical samples (32). From
250 reads unambiguously mapped to subgenomic RNA transcripts, the transcript with the highest median
251 read count across clinical samples was ORF7a, followed by the N-gene, then ORF8, and finally the E-
252 gene (32). Again, this trend is consistent with the ddPCR results presented here. Diagnostic RT-PCR
253 assays which specifically detect ORF7a were not identified in our review. Next-generation sequencing
254 and subsequent bioinformatic pipelines have certain biases as these are longer workflows which often
255 discard low quality or ambiguous sequences (33). By using the same diagnostic primer sets with
256 ddPCR and RT-PCR, many of the biases introduced by next-generation sequencing and bioinformatic
257 pipelines are controlled for in this study, thus increasing the relevance of these results to RT-PCR
258 testing.

259 A limitation of this study is its small sample size of eleven clinical nasopharyngeal swabs. A
260 larger number of clinical samples – and different types – should be tested in the future to confirm the
261 conclusions made here. Furthermore, this study did not show that samples with less ORF1 copies than
262 N gene copies would in fact be more likely to be ORF1 negative, N gene positive, in an RT-PCR test.
263 Future studies could test for a relationship between copy number ratios and rates of inconclusive test
264 results. A strength of this study is that it used two different ddPCR targets for each of the three ORFs
265 of interest.

266 In conclusion, this study proposes a biological explanation for certain inconclusive RT-PCR
267 results. Namely, sub-genomic RNA in clinical samples may increase the likelihood of an N gene target

268 from being positive by RT-PCR. Further studies are required to validate this finding in a larger and
269 more diverse sample set.

270 **Materials and Methods:**

271 **Clinical Sample Collection and Ethics:** This research involved human participants and was
272 performed in accordance with the relevant guidelines and regulations. Informed consent was obtained
273 from all participants as required and was approved by Conjoint Health Research Ethics Board
274 (CHREB) at the University of Calgary (REB18-0107, REB20-0402 and REB20-0444).

275 **RNA Extraction:** All clinical and viral culture samples were extracted with the QIAGEN QIAmp
276 Viral RNA Mini Kit following the kit protocol using centrifugation. A starting volume of 140 μ L of
277 UTM sample or culture fluid was used. RNA was eluted in 60 μ L of AVE buffer. RNA extracts were
278 aliquoted and frozen at -80 °C after extraction so multiple ddPCR assays could be run on the same
279 extracts while keeping the number of freeze-thaw cycles consistent so as to not compromise RNA
280 quality.

281 **Viral Cultures:** Vero Cells (ATCC#CCL-81) were maintained in Minimum Essential Media
282 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 1x non-
283 essential amino acids, and 1x antibiotics/antimycotics. Twenty-four hours before virus infection, Vero
284 cells were seeded into 6-well plates at the density of 5E5 cells/well. For virus culture, Vero cells were
285 infected at MOI = 0.01 in 500 μ L inoculant/well. After one hour of absorption, another 2 mL of
286 Minimum essential Media supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 1x non-
287 essential amino acids, and 1x antibiotics/antimycotics (SF-MEM) was added into each well. Virus
288 culture were maintained at 37 °C with 5% CO₂. At designated time point, cells were scraped off from
289 each well with media and centrifuged at 2000xg for 10 min. Supernatant (2 mL) were collected and the
290 cell pellets and ~0.5 mL media were collected as cell lysate. Cell lysates were frozen and thawed twice

291 to release virus and RNAs from cells before assays. Vero cells were seeded at 2E5 cells/well in 24-
292 well plates one day before the assay. One hundred microliter of inoculant from a serial 10-fold dilution
293 were added in duplicated wells. After one hour of absorption, another 1 mL of SF-MEM with 1%
294 carboxymethylcellulose was added into each well. Plates were maintained at 37 °C with 5% CO₂ for 3
295 days before fixation and staining. Cells were fixed/stained with a solution containing 0.13% Crystal
296 violet, 5.26% ethanol, and 11.7% formaldehyde solution for at least one hour. Plaque counting were
297 performed on an LED light box.

298
299 **Droplet Digital PCR (ddPCR):** ddPCR was performed on a Bio-Rad (Hercules, CA) system
300 consisting of an AutoDG automated droplet generator, PX1 PCR plate sealer, C1000 Touch thermal
301 cycler with 96-deep well reaction module, and a QX200 droplet reader. The details of each ddPCR
302 assay used and evaluated in this study are listed in Table S2.

303 For the N1, N2, and RNase P assays, the Bio-Rad SARS-CoV-2 ddPCR kit was used according
304 to the published instructions for use (19). All remaining ddPCR assays used the Bio-Rad One Step
305 Advanced Kit for Probes as per the manufacturer protocol, modified only to use 9.9 µL of extracted
306 RNA per reaction pre-AutoDG handling step. For the serial dilution of sample 1 and the quantification
307 of samples 1, 6, 8, 9, and 10, the China CDC ORF1 ddPCR was run using RNA which went through
308 an extra freeze-thaw step relative to the RNA used to quantify the other targets.

309
310 **Reverse Transcriptase PCR (RT-PCR):** RT-PCR was performed on a Bio-Rad CFX-96 real-time
311 thermocycler. The same primers and probes used for ddPCR were used for RT-PCR with the exception
312 of the US CDC N2 probe which was used entirely as a FAM probe for RT-PCR. For the Corman E
313 gene RT-PCR, Many samples had less than 5 µL of RNA added to them (due to insufficient quantities

314 remaining) and the RNA went through an extra freeze-thaw step compared to the other RT-PCR
315 assays. Cycle threshold (Ct) values were calculated using the default method (single horizontal
316 threshold for all reactions). Details of each assay are provided in Table S3.

317
318 **Data Analysis:** Analysis of ddPCR data was performed using QX Manager 1.2 Standard Edition.
319 Droplets were clustered manually in 2D amplitude mode. Graphs were made with MATLAB R2020b.
320 Statistical analysis was performed in R Studio (R 4.1.2) and MATLAB R2020b. Permutational
321 analysis of variance was performed with RVAideMemoire 0.9-80 (32).

322
323 **Funding:** This work was funded by Canadian Institutes of Health Research (NFRFR-2019-00015) and
324 Canada Foundation for Innovation grant (EO 40999).

325
326 **Acknowledgments:** We thank Claude Lachance and Ilya Grigoryev (Bio-Rad technical support) for
327 help adapting RT-PCR assays for ddPCR.

328
329 **Author Contributions (CRediT Taxonomy):** Noah B. Toppings: Formal analysis, methodology,
330 investigation, visualization, writing – original draft preparation, writing – review and editing.

331 Lisa K. Oberding: Formal analysis, methodology, investigation, writing – review and editing.

332 Yi-Chan Lin: Formal analysis, investigation, writing – review and editing.

333 David Evans: Funding acquisition, conceptualization – review and editing.

334 Dylan R. Pillai: Supervision, funding acquisition, conceptualization, writing – review and editing.

335

336

337

338 **References:**

- 339 1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019
340 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020 Jan
341 23;25(3):2000045.
- 342 2. Centers for Disease Control and Prevention. CDC 2019–Novel Coronavirus (2019-nCoV) Real-
343 Time RT-PCR Diagnostic Panel For Emergency Use Only Instructions for Use Revision 01
344 [Internet]. 2020 [cited 2020 Nov 4]. Available from:
345 <http://www.mlpla.mil.cn/dzfw/yhjy/xgzl/202002/P020200210749561366112.pdf>
- 346 3. Institute_Pasteur. Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-2. 2020.
- 347 4. Pabbaraju K, Wong AA, Douesnard M, Ma R, Gill K, Dieu P, et al. Development and validation
348 of RT-PCR assays for testing for SARS-CoV-2. *Off J Assoc Med Microbiol Infect Dis Canada*
349 [Internet]. 2021 [cited 2021 Apr 26];e20200026. Available from:
350 <https://jammi.utpjournals.press/doi/pdf/10.3138/jammi-2020-0026>
- 351 5. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with
352 human respiratory disease in China. *Nature* [Internet]. 2020 Mar 12 [cited 2021 Feb
353 12];579(7798):265–9. Available from: <https://doi.org/10.1038/s41586-020-2008-3>
- 354 6. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
355 associated with a new coronavirus of probable bat origin. *Nature* [Internet]. 2020 Mar 12 [cited
356 2021 Feb 12];579(7798):270–3. Available from: <https://doi.org/10.1038/s41586-020-2012-7>
- 357 7. Ziegler K, Steininger P, Ziegler R, Steinmann J, Korn K, Ensser A. SARS-CoV-2 samples may
358 escape detection because of a single point mutation in the N gene. *Eurosurveillance* [Internet].
359 2020 Oct 1 [cited 2021 Oct 11];25(39). Available from: [/labs/pmc/articles/PMC7531073/](https://labs.pmc/articles/PMC7531073/)

- 360 8. Artesi M, Bontems S, Göbbels P, Franckh M, Maes P, Boreux R, et al. A Recurrent Mutation at
361 Position 26340 of SARS-CoV-2 Is Associated with Failure of the E Gene Quantitative Reverse
362 Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay. *J Clin Microbiol*
363 [Internet]. 2020 Oct 1 [cited 2021 Oct 9];58(10). Available from:
364 /labs/pmc/articles/PMC7512182/
- 365 9. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
366 transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* [Internet]. 2021 Mar 25
367 [cited 2021 Oct 10];593(7858):266–9. Available from: [https://www.nature.com/articles/s41586-](https://www.nature.com/articles/s41586-021-03470-x)
368 021-03470-x
- 369 10. Hu X, Zhu L, Luo Y, Zhao Q, Tan C, Chen X, et al. Evaluation of the clinical performance of
370 single-, dual-, and triple-target SARS-CoV-2 RT-qPCR methods. *Clin Chim Acta* [Internet].
371 2020 Dec 1 [cited 2021 Oct 9];511:143. Available from: /labs/pmc/articles/PMC7550050/
- 372 11. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2
373 Transcriptome. *Cell*. 2020 May 14;181(4):914-921.e10.
- 374 12. Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-Ronen Y,
375 et al. The coding capacity of SARS-CoV-2. *Nature* [Internet]. 2021 Jan 7 [cited 2021 May
376 12];589(7840):125–30. Available from: <https://doi.org/10.1038/s41586-020-2739-1>
- 377 13. Singanayagam A, Patel M, Charlett A, Bernal JL, Saliba V, Ellis J, et al. Duration of
378 infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19,
379 England, January to May 2020. *Eurosurveillance*. 2020;25(32):1–5.
- 380 14. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA
381 load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients
382 from infectious disease wards. *Eur J Clin Microbiol Infect Dis*. 2020 Jun 1;39(6):1059–61.

- 383 15. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity
384 and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. *Nat Microbiol*
385 [Internet]. 2020 Oct 1 [cited 2021 Mar 28];5(10):1299–305. Available from:
386 <https://doi.org/10.1038/s41564-020-0761-6>
- 387 16. Jawade K, Sinha AY, Bhagat S, Bhowmick S, Chauhan B, Kaginkar S, et al. A novel ORF1a-
388 based SARS-CoV-2 RT-PCR assay to resolve inconclusive samples. *Int J Infect Dis* [Internet].
389 2021 May 1 [cited 2021 Oct 11];106:395. Available from: /labs/pmc/articles/PMC8036167/
- 390 17. SD_Biosensor. STANDARD M nCoV Real-Time Detection kit STANDARD M nCoV Real-
391 Time Detection kit For Use Under the Emergency Use Authorization (EUA) Only Instructions
392 for Use (IFU). 2020.
- 393 18. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
394 transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* [Internet]. 2021 [cited 2021
395 Apr 15]; Available from: <https://doi.org/10.1038/s41586-021-03470-x>
- 396 19. Bio-Rad. Bio-Rad SARS-CoV-2 ddPCR Test Qualitative assay for use on the QX200™ and
397 QXDx™ Droplet Digital™ PCR Systems Instructions For Use. Vol. 12013769. 2020.
- 398 20. Sène M-A, Kiesslich S, Djambazian H, Ragoussis J, Xia Y, Kamen AA. Haplotype-resolved de
399 novo assembly of the Vero cell line genome. *npj Vaccines* [Internet]. 2021 [cited 2021 Nov
400 4];6. Available from: <https://doi.org/10.1038/s41541-021-00358-9>
- 401 21. Viral_Vectors_and_Vaccines_Bioprocessing Group M. PREDICTED: Chlorocebus sabaeus
402 ribonuclease P/MRP subunit p30 (RPP30), - Nucleotide - NCBI [Internet]. NCBI GenBank.
403 2020 [cited 2021 Nov 4]. Available from:
404 [https://www.ncbi.nlm.nih.gov/nucleotide/XM_007963522.2?report=genbank&log\\$=nuclalign&](https://www.ncbi.nlm.nih.gov/nucleotide/XM_007963522.2?report=genbank&log$=nuclalign&blast_rank=1&RID=S8B4SKKR013)
405 [blast_rank=1&RID=S8B4SKKR013](https://www.ncbi.nlm.nih.gov/nucleotide/XM_007963522.2?report=genbank&log$=nuclalign&blast_rank=1&RID=S8B4SKKR013)

- 406 22. Centres for Disease Control and Prevention. Real-time RT-PCR Primers and Probes for
407 COVID-19 | CDC [Internet]. cdc.gov. 2020 [cited 2020 Nov 3]. Available from:
408 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>
- 409 23. Eder PS, Kekuda R, Stolc V, Altman S. Characterization of two scleroderma autoimmune
410 antigens that copurify with human ribonuclease P. Proc Natl Acad Sci [Internet]. 1997 Feb 18
411 [cited 2021 Nov 4];94(4):1101–6. Available from: <https://www.pnas.org/content/94/4/1101>
- 412 24. Eder PS. Human RNaseP protein p30 (RPP30) mRNA, complete cds - Nucleotide - NCBI
413 [Internet]. NCBI GenBank. 1997 [cited 2021 Nov 4]. Available from:
414 [https://www.ncbi.nlm.nih.gov/nucleotide/U77665.1?report=genbank&log\\$=nucltop&blast_rank](https://www.ncbi.nlm.nih.gov/nucleotide/U77665.1?report=genbank&log$=nucltop&blast_rank=11&RID=S8C6R07H013)
415 [=11&RID=S8C6R07H013](https://www.ncbi.nlm.nih.gov/nucleotide/U77665.1?report=genbank&log$=nucltop&blast_rank=11&RID=S8C6R07H013)
- 416 25. Lefever S, Pattyn F, Hellemans J, Vandesompele J. Single-nucleotide polymorphisms and other
417 mismatches reduce performance of quantitative PCR assays. Clin Chem. 2013;59(10):1470–80.
- 418 26. Vaidya NK, Bloomquist A, Perelson AS. Modeling Within-Host Dynamics of SARS-CoV-2
419 Infection: A Case Study in Ferrets. Viruses 2021, Vol 13, Page 1635 [Internet]. 2021 Aug 18
420 [cited 2021 Nov 2];13(8):1635. Available from: [https://www.mdpi.com/1999-](https://www.mdpi.com/1999-4915/13/8/1635/htm)
421 [4915/13/8/1635/htm](https://www.mdpi.com/1999-4915/13/8/1635/htm)
- 422 27. Ghosh S, Dellibovi-Ragheb TA, Kerviel A, Pak E, Qiu Q, Fisher M, et al. β -Coronaviruses Use
423 Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway. Cell [Internet]. 2020 Dec
424 10 [cited 2021 Nov 2];183(6):1520. Available from: [/labs/pmc/articles/PMC7590812/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7590812/)
- 425 28. Telwatte S, Kumar N, Vallejo-Gracia A, Kumar GR, Lu CM, Ott M, et al. Novel RT-ddPCR
426 assays for simultaneous quantification of multiple noncoding and coding regions of SARS-
427 CoV-2 RNA. J Virol Methods. 2021 Jun 1;292:114115.
- 428 29. Telwatte S, Martin HA, Marczak R, Fozouni P, Vallejo-Gracia A, Kumar GR, et al. Novel RT-

- 429 ddPCR assays for measuring the levels of subgenomic and genomic SARS-CoV-2 transcripts.
430 Methods. 2021 Apr 18;
- 431 30. Dimcheff DE, Valesano AL, Rumfelt KE, Fitzsimmons WJ, Blair C, Mirabelli C, et al. Severe
432 Acute Respiratory Syndrome Coronavirus 2 Total and Subgenomic RNA Viral Load in
433 Hospitalized Patients. J Infect Dis [Internet]. 2021 Oct 28 [cited 2021 Dec 8];224(8):1287–93.
434 Available from: <https://academic.oup.com/jid/article/224/8/1287/6236119>
- 435 31. Marchio A, Batejat C, Vanhomwegen J, Feher · Maxence, Grassin Q, Chazal · Maxime, et al.
436 ddPCR increases detection of SARS-CoV-2 RNA in patients with low viral loads. 2021 [cited
437 2021 Dec 8];166:2529–40. Available from: <https://doi.org/10.1007/s00705-021-05149-0>
- 438 32. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in
439 diagnostic samples are not an indicator of active replication. Nat Commun [Internet]. 2020 Dec
440 1 [cited 2021 Mar 30];11(1):1–13. Available from: <https://doi.org/10.1038/s41467-020-19883-7>
- 441 33. D’Argenio V, Casaburi G, Precone V, Salvatore F. Comparative metagenomic analysis of
442 human gut microbiome composition using two different bioinformatic pipelines. Biomed Res
443 Int. 2014;2014.
- 444 34. Herv M. RVAideMemoire: Testing and Plotting Procedures for Biostatistics version 0.9-80
445 from CRAN [Internet]. 2021 [cited 2021 Nov 30]. Available from:
446 <https://rdrr.io/cran/RVAideMemoire/>
447

448 **Tables**

449 **Table 1.** A hypothetical example of a COVID-19 RT-PCR results interpretation guide. A control assay
450 which targets a human gene, or externally added control material, is often run to ensure that sample
451 collection and nucleic acid extraction was performed properly and to ensure that amplification is not
452 being inhibited by the sample.

453

RT-PCR Target	Assay Result				
E gene	-	+	-	+	-
RdRP	-	+	-	-	+
RNase P (internal control)	+	+/-	-	+/-	+/-
COVID-19 Test Result	COVID-19 Not Detected	COVID-19 Positive	Invalid	Inconclusive	Inconclusive

454

455

456

457

458

459

460

461

462

463

464

465

466

467 **Figure Legends**

468

469 **Figure 1. Simplified drawing of SARS-CoV-2 genome replication and transcription showing a**
470 **subset of the canonical sub-genomic RNAs.** The approximate locations of the ddPCR assays used in
471 this study are indicated. After infecting a cell, the SARS-CoV-2 genome gets transcribed to make
472 either (full length) antisense genomic RNA (the replicative form) or antisense sub-genomic RNA
473 (11,12). Sub-genomic RNAs are produced via discontinuous transcription and are considered to be
474 ‘nested’ because they all start from the same 3’ end of the genome (11,12). Antisense genomes can
475 then be transcribed to make +sense genomes which can complete this cycle again or be encapsidated
476 inside a virion (11,12,32). Antisense sub-genomic RNA can be transcribed to make +sense sub-
477 genomic RNA which can be translated to make the protein encoded at the 5’ end of the sub-genomic
478 RNA molecule (11,12). Diagnostic primer sets for RT- and ddPCR amplify all RNA species
479 containing their target sequence, regardless of whether the RNA is sense or antisense, genomic or sub-
480 genomic.

481

482 **Figure 2. Triplicate serial 10-fold dilution of a clinical nasopharyngeal swab (sample 1) tested by**
483 **RT-PCR and quantified by ddPCR.** Dilutions from 10-fold to 1 million-fold are shown. Error bars
484 show ± 1 standard deviation from the arithmetic mean of triplicate ddPCR counts. Triplicate RT-PCR
485 Ct values were averaged to simplify interpretation. RT-PCR reactions which did not amplify (only at
486 the 1 million-fold dilution) were excluded from the analysis. The 1 million-fold dilution for the US
487 CDC N2 target is not shown because the RT-PCR did not amplify for any replicates.

488

489 **Figure 3. Triplicate serial 10-fold dilution of a clinical nasopharyngeal swab tested by RT-PCR**
490 **and quantified by ddPCR.** Linear regression with 95% prediction bands and adjusted R^2 shown.

491 Dilutions from 10-fold to 1 million-fold are shown. If either the RT-PCR or the ddPCR reaction did
492 not amplify, the replicate was excluded from the analysis.

493

494 **Figure 4. A) Growth curve of SARS-CoV-2 cultured in Vero CCL81 cells over 48 hours.** The
495 infectivity of the hour zero time point is calculated based on the intended number of pfu in the
496 inoculum at the start of the infection (10,000 pfu/ 2.5 mL media) (multiplicity of infection = 0.01). **B)**

497 **Mean specific infectivity of SARS-CoV-2 cultures is highest in cell lysates and just after the**
498 **eclipse phase of growth.** The copies/mL of all six ddPCR targets was averaged and then divided by
499 pfu/mL to yield mean specific infectivity. Supernatants and cell lysates were compared with the Mann-
500 Whitney U-test (n.s.: $p > 0.05$). HPI: hours post-infection. Error bars show ± 1 standard deviation from
501 the arithmetic mean of 3 replicates. The inoculum was not replicated (n=1).

502

503 **Figure 5.** Relative abundance of each ddPCR target for SARS-CoV-2 cultures at each time point, and
504 for each culture fraction. For each sample, the copies of each target, indicated in the left column, was
505 divided by the copies of each target, indicated in the bottom row. Each cell was colored based on the
506 arithmetic mean of 3 replicates.

507

508 **Figure 6. Clinical nasopharyngeal swabs quantified by ddPCR.** *The counts shown for samples 1
509 and 2 are from a 1000-fold dilution (corrected for the dilution factor) due to signal overload when
510 quantifying the undiluted sample.

511

512 **Figure 7. Relative abundance of each ddPCR target in clinical samples.** Mean (95% CI) copy
513 ratios (n = 11) between all SARS-CoV-2 ddPCR assays for each clinical nasopharyngeal swab. For
514 each sample, the copies of each target, indicated in the left column, was divided by the copies of each
515 target, indicated in the bottom row. Following this, the arithmetic mean and 95% CI of the eleven
516 ratios were calculated for each cell and a shade of blue or red was assigned based on the value.

517

518 **Figure 8. Comparison of clinical samples to viral cultures by the relative abundance of each**
519 **ddPCR target.** The mean copy ratios from the cultured samples (Figure 5) were subtracted from the
520 mean copy ratios from the clinical sample set (Figure 7) (clinical – culture).

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537 **Supporting Information Legends:**

538 **Figure S1.** Standard curves of copies versus pfu for ddPCR targets using *in vitro* cultured SARS-CoV-

539 2

540 **Table S1.** US CDC N2 RT-PCR Ct values of the eleven frozen clinical nasopharyngeal swabs used in

541 this study.

542 **Figure S2.** Quantification of the Exact Diagnostics SARS-CoV-2 quantitative positive control by each

543 ddPCR target.


544 **Figure S3.** Specific infectivity of SARS-CoV-2 cultured in Vero CCL81 cells.


545 **Table S2.** Details of ddPCR assays used in this study.







546 **Table S3.** Details of RT-PCR assays used in this study.

547



548









RT-PCR Ct value





6 Hours Post-Infection

48 Hours Post-Infection

Culture Supernatant



Cell Lysate



Legend

0.10

0.40


0.70

1.00

1.43

2.50

10.00



Legend						US CDC N2	Numerator
0.50					1.02 (0.96 - 1.08)	US CDC N1	
0.75				0.65 (0.60 - 0.71)	0.66 (0.60 - 0.73)	APL E	
1.00			0.99 (0.92 - 1.06)	0.64 (0.58 - 0.70)	0.65 (0.59 - 0.71)	Corman E	
1.33		0.91 (0.77 - 1.05)	0.89 (0.76 - 1.02)	0.59 (0.47 - 0.70)	0.59 (0.48 - 0.71)	China CDC ORF1	
2.00	1.13 (1.05 - 1.21)	1.01 (0.90 - 1.12)	0.99 (0.91 - 1.06)	0.65 (0.56 - 0.74)	0.66 (0.57 - 0.74)	IP2 ORF1	
IP2 ORF1	China CDC ORF1	Corman E	APL E	US CDC N1	US CDC N2		
Denominator							

